C‑type lectin family XIV members and angiogenesis (Review)
- Authors:
- Supriya Borah
- Dileep Vasudevan
- Rajeeb K. Swain
-
Affiliations: Institute of Life Sciences, Bhubaneswar, Odisha 751023, India - Published online on: August 16, 2019 https://doi.org/10.3892/ol.2019.10760
- Pages: 3954-3962
This article is mentioned in:
Abstract
 |
 |
|
Risau W: Mechanisms of angiogenesis. Nature. 386:671–674. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Klagsbrun M and D'Amore PA: Regulators of angiogenesis. Ann Review Physiol. 53:217–239. 1991. View Article : Google Scholar | |
|
Folkman J: Fundamental concepts of the angiogenic process. Curr Mol Med. 3:643–651. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Patel-Hett S and D'Amore PA: Signal transduction in vasculogenesis and developmental angiogenesis. Int J Dev Biol. 55:353–363. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Neve A, Cantatore FP, Maruotti N, Corrado A and Ribatti D: Extracellular matrix modulates angiogenesis in physiological and pathological conditions. Biomed Res Int. 2014:7560782014. View Article : Google Scholar : PubMed/NCBI | |
|
Bischoff J: Cell adhesion and angiogenesis. J Clin Inves. 99:373–376. 1997. View Article : Google Scholar | |
|
Ramjaun AR and Hodivala-Dilke K: The role of cell adhesion pathways in angiogenesis. Int J Biochem Cell Biol. 41:521–530. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mignatti P and Rifkin DB: Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein. 49:117–137. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Lamalice L, Le Boeuf F and Huot J: Endothelial cell migration during angiogenesis. Circ Res. 100:782–794. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Conway EM, Collen D and Carmeliet P: Molecular mechanisms of blood vessel growth. Cardiovasc Res. 49:507–521. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Papetti M and Herman IM: Mechanisms of normal and tumor-derived angiogenesis. American journal of physiology. Cell Physiol. 282:C947–C970. 2002. View Article : Google Scholar | |
|
Dusse LM, Carvalho MG, Getliffe K, Voegeli D, Cooper AJ and Lwaleed BA: Increased circulating thrombomodulin levels in pre-eclampsia. Clin Chim Acta. 387:168–171. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wada H, Minamikawa K, Wakita Y, Nakase T, Kaneko T, Ohiwa M, Tamaki S, Deguchi K, Shirakawa S, Hayashi T, et al: Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation. Am J Hematol. 44:85–88. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Mori Y, Wada H, Okugawa Y, Tamaki S, Nakasaki T, Watanabe R, Gabazza EC, Nishikawa M, Minami N and Shiku H: Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Clin Appl Thromb Hemost. 7:5–9. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Stratton RJ, Pompon L, Coghlan JG, Pearson JD and Black CM: Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension. Ann Rheum Dis. 59:132–134. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K and Ueda R: Circulating thrombomodulin levels are related to latent progression of atherosclerosis in hypertensive patients. Hypertens Res. 26:479–483. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Papadopoulos DP, Thomopoulos C, Mourouzis I, Kotrotsou A, Sanidas E, Papazachou U, Daskalaki M and Makris TK: Masked hypertension unfavourably affects haemostasis parameters. Blood Press. 20:218–221. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Maia M, de Vriese A, Janssens T, Moons M, van Landuyt K, Tavernier J, Lories RJ and Conway EM: CD248 and its cytoplasmic domain: A therapeutic target for arthritis. Arthritis Rheum. 62:3595–3606. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lax S, Hou TZ, Jenkinson E, Salmon M, MacFadyen JR, Isacke CM, Anderson G, Cunningham AF and Buckley CD: CD248/Endosialin is dynamically expressed on a subset of stromal cells during lymphoid tissue development, splenic remodeling and repair. FEBS Lett. 581:3550–3556. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Jeon JW, Jung JG, Shin EC, Choi HI, Kim HY, Cho ML, Kim SW, Jang YS, Sohn MH, Moon JH, et al: Soluble CD93 induces differentiation of monocytes and enhances TLR responses. J Immunol. 185:4921–4927. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Moosig F, Fahndrich E, Knorr-Spahr A, Böttcher S, Ritgen M, Zeuner R, Kneba M and Schröder JO: C1qRP (CD93) expression on peripheral blood monocytes in patients with systemic lupus erythematosus. Rheumatol Int. 26:1109–1112. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
van der Net JB, Oosterveer DM, Versmissen J, Defesche JC, Yazdanpanah M, Aouizerat BE, Steyerberg EW, Malloy MJ, Pullinger CR, Kastelein JJ and Kane JP: Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia. Eur Heart J. 29:2195–2201. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Drickamer K: Demonstration of carbohydrate-recognition activity in diverse proteins which share a common primary structure motif. Biochem Soci Trans. 17:13–15. 1989. View Article : Google Scholar | |
|
Drickamer K: C-type lectin-like domains. Curr Opinion Struct Biol. 9:585–590. 1999. View Article : Google Scholar | |
|
Drickamer K and Fadden AJ: Genomic analysis of C-type lectins. Biochem Soci Symp. 59–72. 2002. View Article : Google Scholar | |
|
Zelensky AN and Gready JE: C-type lectin-like domains in Fugu rubripes. BMC Genomics. 5:512004. View Article : Google Scholar : PubMed/NCBI | |
|
Drickamer K: Evolution of Ca(2+)-dependent animal lectins. Prog Nucleic Acid Res Mol Biol. 45:207–232. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Zelensky AN and Gready JE: The C-type lectin-like domain superfamily. FEBS J. 272:6179–6217. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Rho SS, Choi HJ, Min JK, Lee HW, Park H, Park H, Kim YM and Kwon YG: Clec14a is specifically expressed in endothelial cells and mediates cell to cell adhesion. Biochem Biophys Res Commun. 404:103–108. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mura M, Swain RK, Zhuang X, Vorschmitt H, Reynolds G, Durant S, Beesley JF, Herbert JM, Sheldon H, Andre M, et al: Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene. 31:293–305. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Du J, Yang Q, Luo L and Yang D: C1qr and C1qrl redundantly regulate angiogenesis in zebrafish through controlling endothelial Cdh5. Biochem Biophys Res Commun. 483:482–487. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Masiero M, Simoes FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, et al: A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 24:229–241. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Delcourt N, Quevedo C, Nonne C, Fons P, O'Brien D, Loyaux D, Diez M, Autelitano F, Guillemot JC, Ferrara P, et al: Targeted identification of sialoglycoproteins in hypoxic endothelial cells and validation in zebrafish reveal roles for proteins in angiogenesis. J Biol Chem. 290:3405–3417. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ki MK, Jeoung MH, Choi JR, Rho SS, Kwon YG, Shim H, Chung J, Hong HJ, Song BD and Lee S: Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro. Oncogene. 32:5449–5457. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kim TK, Park CS, Jang J, Kim MR, Na HJ, Lee K, Kim HJ, Heo K, Yoo BC, Kim YM, et al: Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a. Mol Oncol. 12:356–372. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zanivan S, Maione F, Hein MY, Hernández-Fernaud JR, Ostasiewicz P, Giraudo E and Mann M: SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers. Mol Cell Proteomics. 12:3599–3611. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Dev KK: Making protein interactions druggable: Targeting PDZ domains. Nat Rev Drug Discov. 3:1047–1056. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kim S, Bell K, Mousa SA and Varner JA: Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol. 156:1345–1362. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Huang X, Ji G, Wu Y, Wan B and Yu L: LAMA4, highly expressed in human hepatocellular carcinoma from Chinese patients, is a novel marker of tumor invasion and metastasis. J Cancer Res Clin Oncol. 134:705–714. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lorenzon E, Colladel R, Andreuzzi E, Marastoni S, Todaro F, Schiappacassi M, Ligresti G, Colombatti A and Mongiat M: MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene. 31:3136–3147. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lugano R, Vemuri K, Yu D, Bergqvist M, Smits A, Essand M, Johansson S, Dejana E and Dimberg A: CD93 promotes beta1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis. J Clin Invest. 128:3280–3297. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Khan KA, Naylor AJ, Khan A, Noy PJ, Mambretti M, Lodhia P, Athwal J, Korzystka A, Buckley CD, Willcox BE, et al: Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface. Oncogene. 36:6097–6108. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Noy PJ, Lodhia P, Khan K, Zhuang X, Ward DG, Verissimo AR, Bacon A and Bicknell R: Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth. Oncogene. 34:5821–5831. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jang J, Kim MR, Kim TK, Lee WR, Kim JH, Heo K and Lee S: CLEC14a-HSP70-1A interaction regulates HSP70-1A-induced angiogenesis. Sci Re. 7:106662017. | |
|
Noy PJ, Swain RK, Khan K, Lodhia P and Bicknell R: Sprouting angiogenesis is regulated by shedding of the C-type lectin family 14, member A (CLEC14A) ectodomain, catalyzed by rhomboid-like 2 protein (RHBDL2). FASEB J. 30:2311–2323. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lee S, Rho SS, Park H, Park JA, Kim J, Lee IK, Koh GY, Mochizuki N, Kim YM and Kwon YG: Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis. J Clin Invest. 127:457–471. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomäki A, Aranda E, et al: VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol. 13:1202–1213. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S and Horiguchi S: Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J. 6:1891–1897. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Conway EM: Thrombomodulin and its role in inflammation. Semin Immunopathol. 34:107–125. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Maruyama I, Bell CE and Majerus PW: Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol. 101:363–371. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Soff GA, Jackman RW and Rosenberg RD: Expression of thrombomodulin by smooth muscle cells in culture: Different effects of tumor necrosis factor and cyclic adenosine monophosphate on thrombomodulin expression by endothelial cells and smooth muscle cells in culture. Blood. 77:515–518. 1991.PubMed/NCBI | |
|
McCachren SS, Diggs J, Weinberg JB and Dittman WA: Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood. 78:3128–3132. 1991.PubMed/NCBI | |
|
Calnek DS and Grinnell BW: Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. Exp Cell Res. 238:294–298. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Huang HC, Shi GY, Jiang SJ, Shi CS, Wu CM, Yang HY and Wu HL: Thrombomodulin-mediated cell adhesion: Involvement of its lectin-like domain. J Biol Chem. 278:46750–46759. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Suehiro T, Shimada M, Matsumata T, Taketomi A, Yamamoto K and Sugimachi K: Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology. 21:1285–1290. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Tabata M, Sugihara K, Yonezawa S, Yamashita S and Maruyama I: An immunohistochemical study of thrombomodulin in oral squamous cell carcinoma and its association with invasive and metastatic potential. J Oral Pathol Med. 26:258–264. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu YY, Shi GY, Wang KC, Ma CY, Cheng TL and Wu HL: Thrombomodulin promotes focal adhesion kinase activation and contributes to angiogenesis by binding to fibronectin. Oncotarget. 7:68122–68139. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P, Flavell RA, Gu H and Guan JL: Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol. 169:941–952. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Peng X, Ueda H, Zhou H, Stokol T, Shen TL, Alcaraz A, Nagy T, Vassalli JD and Guan JL: Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice. Cardiovasc Rese. 64:421–430. 2004. View Article : Google Scholar | |
|
Kao YC, Wu LW, Shi CS, Chu CH, Huang CW, Kuo CP, Sheu HM, Shi GY and Wu HL: Downregulation of thrombomodulin, a novel target of Snail, induces tumorigenesis through epithelial-mesenchymal transition. Mol Cell Biol. 30:4767–4785. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kuo CH, Chen PK, Chang BI, Sung MC, Shi CS, Lee JS, Chang CF, Shi GY and Wu HL: The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen. Blood. 119:1302–1313. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hosaka Y, Higuchi T, Tsumagari M and Ishii H: Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin. Cancer Lett. 161:231–240. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, et al: The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med. 196:565–577. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Hamatake M, Ishida T, Mitsudomi T, Akazawa K and Sugimachi K: Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. Clin Cancer Res. 2:763–766. 1996.PubMed/NCBI | |
|
Tezuka Y, Yonezawa S, Maruyama I, Matsushita Y, Shimizu T, Obama H, Sagara M, Shirao K, Kusano C, Natsugoe S, et al: Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis. Cancer Res. 55:4196–4200. 1995.PubMed/NCBI | |
|
Hanly AM, Redmond M, Winter DC, Brophy S, Deasy JM, Bouchier-Hayes DJ and Kay EW: Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival. Br J Cancer. 94:1320–1325. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Weiler-Guettler H, Chen J, Wilhelm O, Deng Y, Qiu F, Nakagawa K, Klevesath M, Wilhelm S, Böhrer H, et al: Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest. 101:1301–1309. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Lindahl AK, Boffa MC and Abildgaard U: Increased plasma thrombomodulin in cancer patients. Thromb Haemost. 69:112–114. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Salmaggi A, Eoli M, Frigerio S, Ciusani E, Silvani A and Boiardi A: Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. Cancer Lett. 146:169–172. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu YY, Shi GY, Kuo CH, Liu SL, Wu CM, Ma CY, Lin FY, Yang HY and Wu HL: Thrombomodulin is an ezrin-interacting protein that controls epithelial morphology and promotes collective cell migration. FASEB J. 26:3440–3452. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng N, Huo Z, Zhang B, Meng M, Cao Z, Wang Z and Zhou Q: Thrombomodulin reduces tumorigenic and metastatic potential of lung cancer cells by up-regulation of E-cadherin and down-regulation of N-cadherin expression. Biochem Biophys Res Commun. 476:252–259. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shi CS, Shi GY, Chang YS, Han HS, Kuo CH, Liu C, Huang HC, Chang YJ, Chen PS and Wu HL: Evidence of human thrombomodulin domain as a novel angiogenic factor. Circulation. 111:1627–1636. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Pan B, Honda G, Wang X, Hashimoto Y, Ohkawara H, Xu K, Zeng L and Ikezoe T: Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain. Haematologica. 103:1730–1740. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kuo CH, Sung MC, Chen PK, Chang BI, Lee FT, Cho CF, Hsieh TT, Huang YC, Li YH, Shi GY, et al: FGFR1 mediates recombinant thrombomodulin domain-induced angiogenesis. Cardiovasc Res. 105:107–117. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nepomuceno RR, Henschen-Edman AH, Burgess WH and Tenner AJ: cDNA cloning and primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. Immunity. 6:119–129. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Malarstig A, Silveira A, Wagsater D, Öhrvik J, Bäcklund A, Samnegård A, Khademi M, Hellenius ML, Leander K, Olsson T, et al: Plasma CD93 concentration is a potential novel biomarker for coronary artery disease. J Intern Med. 270:229–236. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
McGreal EP, Ikewaki N, Akatsu H, Morgan BP and Gasque P: Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. J Immunol. 168:5222–5232. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Bohlson SS, Silva R, Fonseca MI and Tenner AJ: CD93 is rapidly shed from the surface of human myeloid cells and the soluble form is detected in human plasma. J Immunol. 175:1239–1247. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nepomuceno RR and Tenner AJ: C1qRP, the C1q receptor that enhances phagocytosis, is detected specifically in human cells of myeloid lineage, endothelial cells, and platelets. J Immunol. 160:1929–1935. 1998.PubMed/NCBI | |
|
Langenkamp E, Zhang L, Lugano R, Huang H, Elhassan TE, Georganaki M, Bazzar W, Lööf J, Trendelenburg G, Essand M, et al: Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival. Cancer Res. 75:4504–4516. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bao L, Tang M, Zhang Q, You B, Shan Y, Shi S, Li L, Hu S and You Y: Elevated expression of CD93 promotes angiogenesis and tumor growth in nasopharyngeal carcinoma. Biochem Biophys Res Commun. 476:467–474. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tosi GM, Caldi E, Parolini B, Toti P, Neri G, Nardi F, Traversi C, Cevenini G, Marigliani D, Nuti E, et al: CD93 as a potential target in neovascular age-related macular degeneration. J Cell Physiol. 232:1767–1773. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dieterich LC, Mellberg S, Langenkamp E, Zhang L, Zieba A, Salomäki H, Teichert M, Huang H, Edqvist PH, Kraus T, et al: Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFbeta2 in vascular abnormalization. J Pathol. 228:378–390. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Greenlee MC, Sullivan SA and Bohlson SS: Detection and characterization of soluble CD93 released during inflammation. Inflamm Res. 58:909–919. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Petrenko O, Beavis A, Klaine M, Kittappa R, Godin I and Lemischka IR: The molecular characterization of the fetal stem cell marker AA4. Immunity. 10:691–700. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Bohlson SS, Dy M and Tenner AJ: Modulated interaction of the ERM protein, moesin, with CD93. Immunology. 115:63–73. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Galvagni F, Nardi F, Maida M, Bernardini G, Vannuccini S, Petraglia F, Santucci A and Orlandini M: CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration adhesion and migration. Oncotarget. 7:10090–10103. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Galvagni F, Nardi F, Spiga O, Trezza A, Tarticchio G, Pellicani R, Andreuzzi E, Caldi E, Toti P, Tosi GM, et al: Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium. Matrix Biol. 64:112–127. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kao YC, Jiang SJ, Pan WA, Wang KC, Chen PK, Wei HJ, Chen WS, Chang BI, Shi GY and Wu HL: The epidermal growth factor-like domain of CD93 is a potent angiogenic factor. PLoS One. 7:e516472012. View Article : Google Scholar : PubMed/NCBI | |
|
Orlandini M, Galvagni F, Bardelli M, Rocchigiani M, Lentucci C, Anselmi F, Zippo A, Bini L and Oliviero S: The characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target. Oncotarget. 5:2750–2760. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Christian S, Ahorn H, Koehler A, Eisenhaber F, Rodi HP, Garin-Chesa P, Park JE, Rettig WJ and Lenter MC: Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem. 276:7408–7414. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA and Old LJ: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA. 89:10832–10836. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Bagley RG, Weber W, Rouleau C, Yao M, Honma N, Kataoka S, Ishida I, Roberts BL and Teicher BA: Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. Int J Oncol. 34:619–627. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Christian S, Winkler R, Helfrich I, Boos AM, Besemfelder E, Schadendorf D and Augustin HG: Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. Am J Pathol. 172:486–494. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Becker R, Lenter MC, Vollkommer T, Boos AM, Pfaff D, Augustin HG and Christian S: Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K. FASEB J. 22:3059–3067. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tomkowicz B, Rybinski K, Foley B, Ebel W, Kline B, Routhier E, Sass P, Nicolaides NC, Grasso L and Zhou Y: Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proc Natl Acad Sci USA. 104:17965–17970. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Nanda A, Karim B, Peng Z, Liu G, Qiu W, Gan C, Vogelstein B, St Croix B, Kinzler KW and Huso DL: Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci USA. 103:3351–3356. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Maia M, DeVriese A, Janssens T, Moons M, Lories RJ, Tavernier J and Conway EM: CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer. 11:1622011. View Article : Google Scholar : PubMed/NCBI | |
|
Yeo M, Park HJ, Kim DK, Kim YB, Cheong JY, Lee KJ and Cho SW: Loss of SM22 is a characteristic signature of colon carcinogenesis and its restoration suppresses colon tumorigenicity in vivo and in vitro. Cancer. 116:2581–2589. 2010.PubMed/NCBI | |
|
Nowell CS and Radtke F: Notch as a tumour suppressor. Nat Rev Cancer. 17:145–159. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ohradanova A, Gradin K, Barathova M, Zatovicova M, Holotnakova T, Kopacek J, Parkkila S, Poellinger L, Pastorekova S and Pastorek J: Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2. Br J Cancer. 99:1348–1356. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y and Adjei AA: Targeting angiogenesis in cancer therapy: Moving beyond vascular endothelial growth factor. Oncologist. 20:660–673. 2015. View Article : Google Scholar : PubMed/NCBI |
